These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29739175)

  • 21. Potassium-competitive acid blockers and acid-related disorders.
    Huang KZ; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2024 Jun; 31(3):107-114. PubMed ID: 38483115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
    Andersson K; Carlsson E
    Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potassium-competitive acid blocker-associated gastric mucosal lesions.
    Kubo K; Kimura N; Kato M
    Clin Endosc; 2024 Feb; ():. PubMed ID: 38419167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.
    Horikawa Y; Mizutamari H; Mimori N; Kato Y; Fushimi S; Sato S; Okubo S
    Scand J Gastroenterol; 2018 Feb; 53(2):243-251. PubMed ID: 29214885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
    Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.
    Savarino E; Martinucci I; Furnari M; Romana C; Pellegatta G; Moscatelli A; Bodini G; Marabotto E; Savarino V; de Bortoli N; Blandizzi C
    Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1333-1341. PubMed ID: 27428571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of vonoprazan in patients with erosive esophagitis.
    Zhang M; Xiao Y; Chen M
    Therap Adv Gastroenterol; 2022; 15():17562848221122623. PubMed ID: 36117573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?
    Rawla P; Sunkara T; Ofosu A; Gaduputi V
    World J Gastrointest Pharmacol Ther; 2018 Dec; 9(7):63-68. PubMed ID: 30595950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.
    Shirai Y; Kawami N; Iwakiri K; Kuwana M
    J Scleroderma Relat Disord; 2022 Feb; 7(1):57-61. PubMed ID: 35386943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review.
    Domingues G; Chinzon D; Moraes-Filho JPP; Senra JT; Perrotti M; Zaterka S
    Prz Gastroenterol; 2023; 18(1):47-55. PubMed ID: 37007753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
    Hori Y; Imanishi A; Matsukawa J; Tsukimi Y; Nishida H; Arikawa Y; Hirase K; Kajino M; Inatomi N
    J Pharmacol Exp Ther; 2010 Oct; 335(1):231-8. PubMed ID: 20624992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveillance study.
    Kawai T; Suzuki C; Honda Y; Fernandez JL
    Expert Opin Drug Saf; 2023; 22(5):425-431. PubMed ID: 36264125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility.
    Takahashi N; Take Y
    J Pharmacol Exp Ther; 2018 Feb; 364(2):275-286. PubMed ID: 29180359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
    Hunt RH; Scarpignato C
    Clin Transl Gastroenterol; 2015 Oct; 6(10):e119. PubMed ID: 26513137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data.
    Moraes-Filho JPP; Domingues G; Chinzon D; Guedes JLS; Santos CY; Zaterka S
    Prz Gastroenterol; 2022; 17(4):266-273. PubMed ID: 36514456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soraprazan: setting new standards in inhibition of gastric acid secretion.
    Simon WA; Herrmann M; Klein T; Shin JM; Huber R; Senn-Bilfinger J; Postius S
    J Pharmacol Exp Ther; 2007 Jun; 321(3):866-74. PubMed ID: 17369284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: potassium-competitive acid blockers for the treatment of acid-related disorders.
    Abdel-Aziz Y; Metz DC; Howden CW
    Aliment Pharmacol Ther; 2021 Apr; 53(7):794-809. PubMed ID: 33592125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.